BiotechTube

Olaparib 300mg tablets + Placebo to match olaparib 300mg

Phase 3Active
1 views this week 0 watching⚡ Active
Interest: 44/100
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Platinum Sensitive

Conditions

Platinum Sensitive, BRCA Mutated, Relapsed Ovarian Cancer, Following Complete or Partial Response to Platinum Based Chemotherapy

Trial Timeline

Sep 3, 2013 → Dec 31, 2025

NCT ID
NCT01874353

About Olaparib 300mg tablets + Placebo to match olaparib 300mg

Olaparib 300mg tablets + Placebo to match olaparib 300mg is a phase 3 stage product being developed by AstraZeneca for Platinum Sensitive. The current trial status is active. This product is registered under clinical trial identifier NCT01874353. Target conditions include Platinum Sensitive, BRCA Mutated, Relapsed Ovarian Cancer.

What happened to similar drugs?

0 of 6 similar drugs in Platinum Sensitive were approved

Approved (0) Terminated (2) Active (4)
❌OLAPARIB + PLACEBOAstraZenecaPhase 3
🔄OLAPARIB + Single agent chemotherapyAstraZenecaPhase 3
❌Nemvaleukin and Pembrolizumab Combination + Pembrolizumab + Nemvaleukin + Pegylated Liposomal Doxorubicin (PLD) + Paclitaxel + Topotecan + GemcitabineMerckPhase 3
🔄Rina-S + Paclitaxel + Topotecan + Pegylated liposomal doxorubicin (PLD) + GemcitabineGenmabPhase 3
🔄ZL-2306(nirapairb) + PlacebosZai LabPhase 3
🔄olvimulogene nanivacirepvec + Platinum chemotherapy: carboplatin (preferred) or cisplatin + Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin + Bevacizumab (or biosimilar)GeneluxPhase 3

Hype Score Breakdown

Clinical
17
Activity
12
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01874353Phase 3Active

Competing Products

20 competing products in Platinum Sensitive

See all competitors
ProductCompanyStageHype Score
PRGN-3005 UltraCAR-T cells + PRGN-3005 UltraCAR-T cellsPrecigenPhase 1
27
OSI-906 + erlotinib + placeboAstellas PharmaPhase 2
35
ASP1650Astellas PharmaPhase 2
35
Niraparib + AnlotinibSun PharmaceuticalPhase 2
35
E7050 + CetuximabEisaiPhase 1/2
32
Farletuzumab + PlaceboEisaiPhase 2
35
PLD 40mg/m2 ivgtt q4w +Apatinib 250mg po qd + PLD 40mg/m2 ivgtt q4wJiangsu Hengrui MedicinePhase 2
31
OLAPARIBAstraZenecaPhase 2
35
Batiraxcept + DurvalumabAstraZenecaPhase 1/2
24
cediranib and olaparibAstraZenecaPhase 2
35
Durvalumab and Tremelimumab + AZD1775 and carboplatin (CBPT) + AZD6738 and olaparibAstraZenecaPhase 2
35
olaparib+cediranib combination therapy + durvalumab + olaparib combination therapy + durvalumab + chemotherapy treatment + durvalumab + tremelimumab + chemotherapy treatment + durvalumab + tremelimumab + paclitaxel treatment + durvalumab +chemotherapy treatmentAstraZenecaPhase 2
31
OLAPARIB + PLACEBOAstraZenecaPhase 3
32
ZD4054 Zibotentan + Paclitaxel + Carboplatin + PlaceboAstraZenecaPhase 2
27
OLAPARIB + Single agent chemotherapyAstraZenecaPhase 3
40
TILT-123 + pembrolizumab + pegylated liposomal doxorubicinMerckPhase 1/2
39
OSE2101 + Pembrolizumab 25 MG/ML [Keytruda]MerckPhase 2
39
Nemvaleukin and Pembrolizumab Combination + Pembrolizumab + Nemvaleukin + Pegylated Liposomal Doxorubicin (PLD) + Paclitaxel + Topotecan + GemcitabineMerckPhase 3
32
IBI363+IBI305Innovent BiologicsPhase 2
42
Nivolumab InjectionBristol Myers SquibbPhase 2
35